Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTX-001 in Acute Exacerbation of Schizophrenia
NCT07734493Phase 1Recruiting
- Sponsor
- Leal Therapeutics
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LTX-001 in schizophrenia (3 arms), sponsored by Leal Therapeutics. Primary endpoints: Safety and Tolerability - Adverse Events, Safety and Tolerability - Clinical Laboratory Tests and 16 more. Started Aug 2026; status: recruiting.
02
Drugs
LTX-001
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07734493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734493.